Strategic collaboration to develop advanced radiation oncology applications with industry-leading auto-contouring and treatment planning software
STOCKHOLM – Elekta (EKTA-B.ST) and MIM Software Inc. (MIM), a leading provider of medical image management and artificial intelligence solutions recently acquired by GE HealthCare, announce their collaboration to combine best-in-class solutions for advanced treatment planning in radiation therapy delivery. The strategic collaboration aims to accelerate innovation in software solutions that will benefit clinics with improved workflows, increased productivity and a better user experience, while providing patients with greater precision in their treatments and less time spent in the hospital. Maurits Wolleswinkel, President Linac and Software Solutions at Elekta, said: “While this is an exciting step for both companies, it is a significant development for radiotherapy clinics and their patients. This is a natural expansion of Elekta ONE, combining best-in-class dose planning capabilities with MIM’s proven track record of physician-preferred tools. Clinically, this means delivering enhanced automation and adaptive therapy planning, as well as increased speed and accuracy.” And our vendor-agnostic philosophy ensures that all radiation therapy providers benefit from this collaboration.” The collaboration is expected to drive innovation within treatment planning and leverage Elekta and MIM Software’s respective strengths in regional markets to make solutions available globally. Andrew Nelson, CEO, MIM Software, GE HealthCare, added: “Since its inception in 2003, MIM has played a key role in advancing precision medicine in radiation oncology.” Jonathan Piper, Chief Scientific Officer, MIM Software, GE HealthCare, said: “We have heard the overwhelming demand from our customers for treatment planning software and are proud to announce that we have met the challenge. This is a critical step in streamlining clinical workflows, unlocking precision medicine and expanding our impact on clinicians and patients around the world.” For more information, visit Elekta. This is an adaptation of original content published by Elekta.
